Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
+1.35 (10.34%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.10 - 14.40
52 week 7.50 - 16.50
Open 13.10
Vol / Avg. 1.17M/698,317.00
Mkt cap 357.71M
P/E     -
Div/yield     -
EPS -3.38
Shares 24.84M
Beta 1.69
Inst. own 90%
Aug 8, 2017
Q2 2017 Zogenix Inc Earnings Call - Webcast
Aug 8, 2017
Q2 2017 Zogenix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -315.13% -238.08%
Operating margin -309.84% -251.94%
EBITD margin - -217.86%
Return on average assets -45.10% -25.57%
Return on average equity -99.73% -45.26%
Employees 67 -
CDP Score - -


5858 Horton St Ste 455
EMERYVILLE, CA 94608-2072
United States - Map
+1-510-5508300 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Gail M. Farfel Ph.D. Executive Vice President, Chief Development Officer
Age: 51
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Thierry J P Darcis Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Roger L. Hawley Director
Age: 63
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 52
Bio & Compensation  - Reuters
Mark C. Wiggins Independent Director
Age: 59
Bio & Compensation  - Reuters